NOVELIX [NOVELIX] vs Welcure Drugs [WELCURE] Detailed Stock Comparison

NOVELIX PHARMACEUTICALS LIMITE

BSE
Loading...

Welcure Drugs & Pharmaceuticals Ltd.

BSE
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: NOVELIX PHARMACEUTICALS LIMITE wins in 4 metrics, Welcure Drugs & Pharmaceuticals Ltd. wins in 13 metrics, with 1 ties. Welcure Drugs & Pharmaceuticals Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric NOVELIX PHARMACEUTICALS LIMITE Welcure Drugs & Pharmaceuticals Ltd. Better
P/E Ratio (TTM) 48.76 1.30 Welcure Drugs & Pharmaceuticals Ltd.
Price-to-Book Ratio 3.10 0.28 Welcure Drugs & Pharmaceuticals Ltd.
Debt-to-Equity Ratio 0.00 91.72 Tie
PEG Ratio 0.17 0.01 Welcure Drugs & Pharmaceuticals Ltd.
EV/EBITDA 39.81 2.81 Welcure Drugs & Pharmaceuticals Ltd.
Profit Margin (TTM) 1.41% 12.21% Welcure Drugs & Pharmaceuticals Ltd.
Operating Margin (TTM) 2.65% 12.24% Welcure Drugs & Pharmaceuticals Ltd.
EBITDA Margin (TTM) 2.65% 12.24% Welcure Drugs & Pharmaceuticals Ltd.
Return on Equity 0.48% 2.12% Welcure Drugs & Pharmaceuticals Ltd.
Return on Assets (TTM) 0.31% 0.81% Welcure Drugs & Pharmaceuticals Ltd.
Free Cash Flow (TTM) $-137.91M $-2.22B NOVELIX PHARMACEUTICALS LIMITE
1-Year Return 100.43% -72.38% NOVELIX PHARMACEUTICALS LIMITE
Price-to-Sales Ratio (TTM) 0.91 0.10 Welcure Drugs & Pharmaceuticals Ltd.
Enterprise Value $964.62M $1.26B Welcure Drugs & Pharmaceuticals Ltd.
EV/Revenue Ratio 0.75 0.34 Welcure Drugs & Pharmaceuticals Ltd.
Gross Profit Margin (TTM) 3.21% N/A N/A
Revenue per Share (TTM) $85 $2 NOVELIX PHARMACEUTICALS LIMITE
Earnings per Share (Diluted) $1.13 $0.23 NOVELIX PHARMACEUTICALS LIMITE
Beta (Stock Volatility) 0.50 -1.80 Welcure Drugs & Pharmaceuticals Ltd.

NOVELIX PHARMACEUTICALS LIMITE vs Welcure Drugs & Pharmaceuticals Ltd. Stock Performance Analysis

Loading Price Chart...

NOVELIX
WELCURE

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
NOVELIX PHARMACEUTICALS LIMITE3.46%-2.57%-4.03%-7.95%-20.39%-13.17%
Welcure Drugs & Pharmaceuticals Ltd.-3.70%-6.90%-3.57%-10.00%-52.63%-35.71%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
NOVELIX PHARMACEUTICALS LIMITE100.43%131.88%131.88%131.88%131.88%131.88%
Welcure Drugs & Pharmaceuticals Ltd.-72.38%-21.62%26.09%141.67%93.33%-45.28%

Performance & Financial Health Analysis: NOVELIX PHARMACEUTICALS LIMITE vs Welcure Drugs & Pharmaceuticals Ltd.

MetricNOVELIXWELCURE
Market Information
Market Cap i₹1.16B₹370.78M
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i6,32913,383,901
90 Day Avg. Volume i6,50810,165,552
Last Close₹54.49₹0.26
52 Week Range₹27.94 - ₹70.16₹0.23 - ₹1.44
% from 52W High-22.33%-82.00%
All-Time High₹70.16 (Nov 19, 2025)₹25.00 (Sep 19, 2005)
% from All-Time High-22.33%-98.96%
Growth Metrics
Quarterly Revenue Growth8.13%-1.00%
Quarterly Earnings Growth5.79%1.57%
Financial Health
Profit Margin (TTM) i0.01%0.12%
Operating Margin (TTM) i0.03%0.12%
Return on Equity (TTM) i0.00%0.02%
Debt to Equity (MRQ) i0.0091.72
Cash & Liquidity
Book Value per Share (MRQ)₹17.77₹1.09
Cash per Share (MRQ)₹0.84₹0.02
Operating Cash Flow (TTM) i₹-221,349,560₹-2,249,340,000
Levered Free Cash Flow (TTM) i₹845,200₹21.70M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: NOVELIX PHARMACEUTICALS LIMITE vs Welcure Drugs & Pharmaceuticals Ltd.

MetricNOVELIX (Apr 24, 2026)WELCURE (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i48.761.30
Forward P/E iN/AN/A
PEG Ratio i0.170.01
Price to Sales (TTM) i0.910.10
Price to Book (MRQ) i3.100.28
Market Capitalization
Market Capitalization i₹1.16B₹370.78M
Enterprise Value i₹964.62M₹1.26B
Enterprise Value Metrics
Enterprise to Revenue i0.750.34
Enterprise to EBITDA i39.812.81
Risk & Other Metrics
Beta i0.50-1.80
Book Value per Share (MRQ) i₹17.77₹1.09

Financial Statements Comparison: NOVELIX PHARMACEUTICALS LIMITE vs Welcure Drugs & Pharmaceuticals Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNOVELIX (2025)WELCURE (2025)
Revenue/Sales i307.18M245.50M
Cost of Goods Sold i295.74M205.03M
COGS % of Revenue i96.3%83.5%
Gross Profit i11.45M40.47M
Gross Margin i3.7%16.5%
Research & Development iN/AN/A
Operating Income (EBIT) i1.12M9.61M
Operating Margin i0.4%3.9%
EBITDA i1.66M-9.41M
EBITDA Margin i0.5%-3.8%
Pre-Tax Income i1.23M27.80M
Pre-Tax Income % of Revenue i0.4%11.3%
Income Tax i388,2306.10M
Income Tax % of Revenue i0.1%2.5%
Net Income (Profit) i845,20021.70M
Profit Margin i0.3%8.8%

Balance Sheet & Liquidity Metrics

MetricNOVELIX (2025)WELCURE (2025)
Cash & Equivalents i6.79M1.28M
Total Current Assets i269.33M1.82B
Total Current Assets % of Revenue i87.7%741.9%
Total Current Liabilities i96.67M412.69M
Total Current Liabilities % of Revenue i31.5%168.1%
Long-Term Debt i01.23B
Long-Term Debt % of Revenue i0.0%501.8%
Total Shareholders Equity i175.39M1.03B
Retained Earnings i-18.76M-100.79M
Retained Earnings % of Revenue i-6.1%-41.1%
Property, Plant & Equipment i1.86MN/A

Cash Flow Statement Comparison

MetricNOVELIX (2025)WELCURE (2025)
Operating Cash Flow i-221.35M-2.25B
Operating Cash Flow % of Revenue i-72.1%-916.2%
Capital Expenditures i-1.06M-170,000
Free Cash Flow i-137.91M-2.22B
FCF Margin i-44.9%-904.5%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricNOVELIXWELCURE
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i21.09M1.24B
Float Shares i3.72M6.63M
% Held by Insiders i70.63%85.74%
% Held by Institutions i0.00%0.00%
% Held by Public i29.37%14.26%

Dividend Analysis & Yield Comparison: NOVELIX PHARMACEUTICALS LIMITE vs Welcure Drugs & Pharmaceuticals Ltd.

MetricNOVELIXWELCURE
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A